{
  "ticker": "JNJ",
  "target_date": "2025-06-03",
  "actual_date": "2025-06-03",
  "collected_at": "2025-12-08T11:50:36.249530",
  "price": {
    "open": 152.7,
    "high": 153.55,
    "low": 151.99,
    "close": 152.32763671875,
    "volume": 8209800,
    "change_1d_pct": -0.63,
    "change_7d_pct": 2.05,
    "change_30d_pct": -0.75
  },
  "technicals": {
    "rsi_14": 71.24,
    "sma_20": 150.07,
    "sma_50": 151.66,
    "macd": 0.126,
    "macd_signal": -0.507,
    "macd_histogram": 0.632,
    "bb_upper": 155.51,
    "bb_lower": 144.62,
    "price_vs_sma20_pct": 1.51,
    "price_vs_sma50_pct": 0.44,
    "volume_ratio": 0.96
  },
  "fundamentals": {
    "market_cap": 489231450112,
    "pe_ratio": 19.600386,
    "forward_pe": 19.156603,
    "price_to_book": 6.163232,
    "price_to_sales": 5.309135,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.29,
    "pct_from_52w_low": 44.34
  },
  "macro": {
    "spy": {
      "price": 592.69,
      "change_1d_pct": 0.57,
      "change_7d_pct": 2.93
    },
    "vix": {
      "level": 17.69,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.46
    },
    "dollar_index": {
      "level": 99.25
    },
    "gold": {
      "price": 3350.2
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts",
      "source": "Yahoo",
      "datetime": 1748987115,
      "summary": "Johnson & Johnson (JNJ) closed at $154.42 in the latest trading session, marking a -0.63% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=7ac468d5d454818592596774636290f4d4ed98e156bacaf81860c8b2d13c7f4a"
    },
    {
      "headline": "ASCO25: J&J\u2019s trispecific antibody shows 100% response in Phase I multiple myeloma study",
      "source": "Yahoo",
      "datetime": 1748984269,
      "summary": "First-in-human data for the trispecific antibody \u201csuggest a paradigm shift\u201d for the relapsed/refractory multiple myeloma space.",
      "url": "https://finnhub.io/api/news?id=ce8e1822d27d55a9f9e096725cc21aa8f33f7472166906730f8783b71cdecde7"
    },
    {
      "headline": "Johnson & Johnson's Darzalex Faspro Regimen Improves Progression-Free Survival in Two Phase 3 Myeloma Trials",
      "source": "Yahoo",
      "datetime": 1748965838,
      "summary": "Johnson & Johnson (JNJ) said Tuesday that data from two phase 3 trials show a Darzalex Faspro-based",
      "url": "https://finnhub.io/api/news?id=f32930aa0f8c39405d7df1e4d3b71f9766d7c62f3622818fb4fd1573305a1a8c"
    },
    {
      "headline": "Single infusion of CARVYKTI\u00ae (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma",
      "source": "Yahoo",
      "datetime": 1748961900,
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI\u00ae (ciltacabtagene autoleucel; cilta-cel) achieved p",
      "url": "https://finnhub.io/api/news?id=7371194365655bd726d16a65df6ecc8d0ffa6f8625fd7794f26e0e7d883d5af3"
    },
    {
      "headline": "DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who ",
      "source": "Yahoo",
      "datetime": 1748961900,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced data from two studies highlighting that a DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PF",
      "url": "https://finnhub.io/api/news?id=2a28b288d59bc09b5a89f399496bb495d703c71bb0bcc4b501596e810754fe89"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "13F-HR",
      "date": "2025-05-07",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000238/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    },
    {
      "form": "8-K",
      "date": "2025-04-30",
      "description": "jnj-20250424.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000141/jnj-20250424.htm"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877468.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000138/xslF345X05/wk-form4_1745877468.xml"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877247.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000135/xslF345X05/wk-form4_1745877247.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}